Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process

Brain

Volumn 126, Issue 4, 2003, Pages 770-782

  Confavreux, Christian ^a   Vukusic, Sandra ^a   Adeleine, Patrice ^b  

^a HÔPITAL NEUROLOGIQUE   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

Clinical predictors; Disability; Multiple sclerosis; Prognosis; Progression

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; METHOTREXATE; MITOXANTRONE;

ADULT; AGE; AGED; AMNESIA; ARTICLE; CHILD; CLINICAL FEATURE; DISABILITY; DISEASE COURSE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SCORING SYSTEM; WALKING AID; WHEELCHAIR; ADOLESCENT; COHORT ANALYSIS; DISABLED PERSON; FOLLOW UP; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROGNOSIS; REGRESSION ANALYSIS;

EID: 0037379402     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awg081     Document Type: Article

References (38)

1. Clark VA, Detels R, Visscher BR, Valdiviezo NL, Malmgren RM, Dudley JP. Factors associated with a malignant or benign course of multiple sclerosis. JAMA 1982; 248: 856-60.
2. Compston A, Coles AJ. Multiple sclerosis. Lancet 2002; 359: 1221-31.
3. Confavreux C. Relapses, progression, inflammation and neurodegeneration in multiple sclerosis: a changing view. Adv Clin Neurosci Rehabil 2002; 2: 7-9.
4. Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002; 15: 257-66.
5. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281-300.
6. Confavreux C, Darchy P, Alperovitch A, Aimard G, Devic M. Le sud-Est français, zone 'à haut risque' de Sclérose en Plaques? Presse Med 1987; 16: 622-3.
7. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671-6.
8. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. New Engl J Med 2000; 343: 1430-8.
9. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122: 625-39.
10. Ebers G. Natural history of multiple sclerosis. In: Compston A, Ebers G, Lassman H, McDonald WI, Matthews B, Wekerle H, editors. McAlpine's multiple sclerosis. 3rd ed. London: Churchill Livingstone; 1998. p. 191-221.
11. Fog T, Linnemann F. The course of multiple sclerosis in 73 cases with computer designed curves. Acta Neurol Scand 1970; Suppl 47: 3-175.
12. Fox NC, Jenkins R, Leary SM, Stevenson VL, Losseff NA, Crum WR, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 2000; 54: 807-12.
13. Hyllested K. Lethality, duration and mortality of disseminated sclerosis in Denmark. Acta Psychiatr Scand 1961; 36: 553-64.
14. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998; 51: 765-72.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
16. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL. Studies on the natural history of multiple sclerosis - 8. Early prognostic features of the later course of the illness. J Chronic Dis 1977; 30: 819-30.
17. Leibowitz U, Alter M. Multiple sclerosis. Clues to its cause. Amsterdam: North-Holland; 1973.
18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.
19. McAlpine D. The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 1961; 84: 186-203.
20. Midgard R, Albrektsen G, Riise T, Kvale G, Nyland HI. Prognostic factors for survival in multiple sclerosis: a longitudinal, population-based study in More and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995; 58: 417-21.
21. Minderhoud JM, Van der Hoeven JH, Prange AJA. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand 1988; 78: 10-5.
22. Muller R. Studies on disseminated sclerosis with special reference to symptomatology, course and prognosis. Acta Med Scand 1949; 133 Suppl 222: 1-214.
23. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north-east Scotland. J Neurol Neurosurg Psychiatry 1987; 50: 523-31.
24. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990; 113: 1597-628.
25. Poser S, Hauptvogel H. Clinical data from 418 MS patients in relation to the diagnosis. First experiences with an optical mark reader documentation system. Acta Neurol Scand 1973; 49: 473-9.
26. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
27. Poser S, Poser W, Schlaf G, Firnhaber W, Lauer K, Wolter M, et al. Prognostic indicators in multiple sclerosis. Acta Neurol Scand 1986; 74: 387-92.
28. Riise T, Gronning M, Fernandez O, Lauer K, Midgard R, Minderhoud JM, et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol Scand 1992; 85: 212-8.
29. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. New Engl J Med 1997; 337: 1604-11.
30. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-704.
31. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116: 117-34.
32. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993; 20: 17-29.
33. Schumacher GA, Beebe GW, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al. Problems of experimental trials of therapy in MS: report by the panel on the evaluation of experimental trials of therapy in MS. Ann NY Acad Sci 1965; 122: 552-68.
34. Thygesen P. Prognosis in initial stages of disseminated primary demyelinating disease of central nervous system. Arch Neurol Psychiat 1949; 61: 339-51.
35. Trojano M, Avolio C, Manzari C, Calo A, De Robertis F, Serio G, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995; 58: 300-6.
36. Weinshenker BG, Bass B, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989a; 112: 133-46.
37. Weinshenker BG, Bass B, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 1989b; 112: 1419-28.
38. Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, Ebers G. The natural history of multiple sclerosis: a geographically based study. III. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114: 1045-56.